Trial reportBMC ophthalmology2026
Changes in visual acuity and corneal aberrations after presbyopia correction using micro-monovision multifocal bi-aspheric ablation: six-month results.
Trial report in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimTo assess visual outcomes and corneal aberration changes following micro-monovision multifocal bi-aspheric ablation (PresbyMax monocular) for presbyopia correction.
method25 patients (50 eyes) underwent PresbyMAX monocular treatment. Pre and postoperative evaluations (1 week, 1, 3, and 6 months) included uncorrected distance (UDVA), intermediate (UIVA), near (UNVA), and corrected distance visual acuity (CDVA). Corneal aberration and Strehl ratio (SR) were analyzed within 3-mm and 6-mm zones. The National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25) was used to assess visual function preoperatively and at 6 months postoperatively.
resultAt 6 months, binocular UDVA and UIVA were 0 (− 0.1, 0) logMAR and − 0.1 (− 0.1, 0) logRAD, respectively. Spectacle independence reached 96%, with 96%, 100%, and 96% achieving UDVA ≥ 0.1 logMAR, UIVA ≥ 0.1 logRAD, and UNVA ≥J1. No eyes lost corrected distance visual acuity. In non-dominant eyes, 3-mm corneal zones exhibited negative shifts in fourth-order spherical aberration ([Formula: see text]) and sixth-order spherical aberration ([Formula: see text]) (both p < 0.001). In 6-mm corneal zones, [Formula: see text] exhibited no significant change; however, compared to the dominant eye, it was significantly more negative (p < 0.001). [Formula: see text] increased positively with a statistically significant difference (p < 0.001). NEI-VFQ-25 scores improved from 74.63 (71.70, 81.81) to 91.15 (85.23, 93.08) (p < 0.001).
conclusionThe PresbyMAX protocol enhances near vision by strategically manipulating aberrations to increase depth of focus in the non-dominant eye, while the dominant eye maintains distance and intermediate vision. This synergistic binocular approach achieves satisfactory full-range vision, resulting in a 96% spectacle independence rate and high patient satisfaction. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR2300074821, registration date 2023-08-17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.